Regulatory mechanism of the gastric hyperemic response following barrier disruption: roles of cyclooxygenase-1, the prostaglandin E2/EP1 receptor and sensory neurons
- PMID: 26004410
- DOI: 10.2174/1381612821666150514105248
Regulatory mechanism of the gastric hyperemic response following barrier disruption: roles of cyclooxygenase-1, the prostaglandin E2/EP1 receptor and sensory neurons
Abstract
We herein reviewed the mechanism underlying the gastric hyperemic response following barrier disruption, with a focus on cyclooxygenase (COX) isozymes, prostaglandin (PG) E2, and capsaicin-sensitive afferent neurons. Mucosal damage was induced by exposing the stomach to 20 mM taurocholate (TC) with 50 mM HCl. The TC treatment disrupted surface epithelial cells, and then increased acid back-diffusion and mucosal blood flow (GMBF) in the stomachs of rats or wild-type mice. This hyperemic response in the rat stomach was inhibited by indomethacin without affecting acid back-diffusion, which resulted in the aggravation of lesions. The effect of indomethacin was mimicked by loxoprofen and the selective COX-1 inhibitor, SC-560, but not by the selective COX-2 inhibitor, celecoxib. The GMBF responses induced by TC were similarly observed in the stomachs of wild-type mice and EP3 receptor knockout mice, but not in mice lacking the EP1 receptor or pretreated with an EP1 antagonist. The increase in the GMBF response associated with acid back-diffusion after the TC treatment was also inhibited by the chemical ablation of capsaicin-sensitive afferent neurons, but not capsazepine, a TRPV1 antagonist. Thus, endogenous PGE2 produced by COX-1 plays a role in the gastric hyperemic response following barrier disruption of the stomach by interacting with capsaicin-sensitive afferent neurons, mainly through EP1 receptors, and facilitating the GMBF response to acid back-diffusion. These findings have also contributed to a deeper understanding of mucosal defensive mechanisms following barrier disruption and the development of new strategies for the treatment of gastrointestinal diseases.
Similar articles
-
Gastric ulcerogenic responses following barrier disruption in knockout mice lacking prostaglandin EP1 receptors.Aliment Pharmacol Ther. 2002 Apr;16 Suppl 2:74-82. doi: 10.1046/j.1365-2036.16.s2.21.x. Aliment Pharmacol Ther. 2002. PMID: 11966527
-
Adaptive gastric cytoprotection is mediated by prostaglandin EP1 receptors: a study using rats and knockout mice.J Pharmacol Exp Ther. 2001 Jun;297(3):1160-5. J Pharmacol Exp Ther. 2001. PMID: 11356942
-
Cyclo-oxygenase isozymes in mucosal ulcergenic and functional responses following barrier disruption in rat stomachs.Br J Pharmacol. 1997 Oct;122(3):447-54. doi: 10.1038/sj.bjp.0701399. Br J Pharmacol. 1997. PMID: 9351500 Free PMC article.
-
Prostaglandin EP receptors and their roles in mucosal protection and ulcer healing in the gastrointestinal tract.Adv Clin Chem. 2010;51:121-44. doi: 10.1016/s0065-2423(10)51005-9. Adv Clin Chem. 2010. PMID: 20857620 Review.
-
Gastric cytoprotection by prostaglandin E₂ and prostacyclin: relationship to EP1 and IP receptors.J Physiol Pharmacol. 2014 Feb;65(1):3-14. J Physiol Pharmacol. 2014. PMID: 24622825 Review.
Cited by
-
Pharmacological targeting of gastric mucosal barrier with traditional Chinese medications for repairing gastric mucosal injury.Front Pharmacol. 2023 Jun 8;14:1091530. doi: 10.3389/fphar.2023.1091530. eCollection 2023. Front Pharmacol. 2023. PMID: 37361204 Free PMC article. Review.
-
Inhibition of Aspirin-Induced Gastrointestinal Injury: Systematic Review and Network Meta-Analysis.Front Pharmacol. 2021 Aug 12;12:730681. doi: 10.3389/fphar.2021.730681. eCollection 2021. Front Pharmacol. 2021. PMID: 34475825 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials